Is Your Pet a Candidate for
GLP-1 Weight Loss?
Searching “Ozempic for cats” or “Ozempic for dogs”? The honest status: no GLP-1 drug is FDA-approved for pets yet, and Okava's MEOW-1 cat trial, now dosing, reads out summer 2027. We track every signal so your overweight cat or dog has a plan the day the science lands.
From the team behind GLP-1 Picks : the human-side telehealth tracker. The same diligence, applied to pets.
No FDA-approved GLP-1 exists for pets yet. We'll tell you the day that changes.
GLP-1 Pets tracks every weight-loss drug in the cat and dog pipeline: the trials, the FDA timeline, and the safety data, in plain English.
Okava's MEOW-1 cat trial is dosing now, with topline data due summer 2027. What it could mean for your cat.
Read this →Every trial, filing, and realistic approval date for cat and dog GLP-1 drugs.
Read this →No GLP-1 is FDA-approved for pets yet. The honest status, and the risk of jumping early.
Read this →Stay Ahead in the GLP-1 Pet Drug Market: Get Free Updates
Trial readouts, FDA milestones, and launch news for cat & dog GLP-1 drugs. One email when something real happens, nothing else.
Cats
The Okava MEOW-1 trial puts cats first. Here's what owners need to know.
Is There an Ozempic for Cats?
Short answer: not yet, but cats are the first animals being studied. Two separate feline GLP-1 trials are running right now. Here's what's real.
GLP-1 for Cats: The Drug Class, the Trials, the Timeline
Two active clinical trials are testing pet-specific GLP-1 receptor agonists in overweight cats. Here's what GLP-1 actually is, why it works, and when the first feline drug realistically lands.
Cat Obesity: The Vet-Backed Guide
Feline obesity has reached crisis levels. 61% of US cats are now overweight or obese. Causes, health risks, what's coming, what to do today.
Overweight Cat: What to Do
Your cat is in the majority. 61% of US cats are overweight. Here's the honest, vet-backed method. Cat GLP-1 drugs are coming, but you don't have to wait.
Dogs
No FDA-approved GLP-1 for dogs exists yet. Here's what works today.
Is There an Ozempic for Dogs?
Short answer: not yet, but the first GLP-1 trials in companion animals are running in cats right now. Here's the real status.
Dog Obesity: The Vet-Backed Guide
59% of US dogs are now overweight or obese. The 2019 University of Liverpool study showed it costs them up to 2.5 years of life. Here's what works.
Overweight Dog: What's Actually Going On
If your dog is overweight, you're in the majority: APOP's vet survey put US canine overweight/obesity at 59%. Here's the honest, vet-backed answer.
Why Your Labrador Is Always Hungry
It's not your fault, and it's not really your Lab's fault either. Cambridge researchers identified a gene deletion in roughly 25% of Labradors that genetically wires them to seek food constantly. Here's the science, and what actually works.
Dog Weight Loss: The Method That Works
The Association for Pet Obesity Prevention's most recent vet survey put the percentage of overweight or obese US dogs at 59%. Here's how to fix it without crash dieting or waiting for canine GLP-1.
Best Dog Food for Weight Loss
The top three vet-recommended weight management foods compared, with specs sourced directly from manufacturer guaranteed analysis.
Low Fat Dog Food: Complete Guide
For pancreatitis recovery, sensitive stomachs, and hyperlipidemia. Prescription and over-the-counter options compared.
The Pipeline
Trials, regulatory milestones, and the historical context behind every pet GLP-1 drug.
What Is MEOW-1?
MEOW-1 is the world's first clinical trial of a pet-specific GLP-1 weight loss drug. Run by Okava, in cats, with results due summer 2026.
MEOW-1 Results: Live Tracker
When Okava publishes the MEOW-1 cat GLP-1 trial readout this summer, we'll update this page with the full data within hours. Until then: here's what we're watching for.
OKV-119: The Drug, The Implant, The Trial
OKV-119 is Okava Pharmaceuticals' investigational subcutaneous implant releasing exenatide: the active ingredient in Byetta and Bydureon, over approximately six months in cats.
Akston AKS-562c: INAD Filed, Pilot Field Study Initiated in Cats
AKS-562c has an active Investigational New Animal Drug (INAD) designation with FDA-CVM and is now initiating a pilot field safety and effectiveness study in client-owned cats: a significant regulatory step beyond the Cornell lab-setting trial and the ACVIM Forum safety presentation. Separately, Akston is developing a canine-specific version of AKS-562c, making it the first dual-species GLP-1 program in veterinary pharma. We're tracking the full regulatory path to approval.
AKS-562c: Akston's Once-Weekly Cat GLP-1 Injection
AKS-562c is Akston Biosciences' investigational GLP-1 receptor agonist: a novel Fc-fusion protein delivered as a once-weekly subcutaneous injection in cats. Cornell trial readout expected Q2-Q3 2026.
LOY-002: The Canine Longevity Drug Setting the FDA Template
Loyal Pharma closed a $100M Series C in February 2026 and is now targeting a potential market launch before the end of 2026, which would make LOY-002 the first drug ever approved to extend lifespan in any species. Two of three FDA technical sections are accepted.
Pet GLP-1 Trial Tracker
Live tracker for the two GLP-1 weight management trials in companion animals: Okava's OKV-119 implant and Akston's AKS-562c injection.
Slentrol: The Dog Weight Loss Drug That Got Pulled
Slentrol was the first and only FDA-approved canine weight loss drug. Approved 2007, voluntarily discontinued in 2013. Here's the full story.
We'll tell you the day pet GLP-1 lands.
Okava MEOW-1 trial results are due summer 2027. Real FDA approval for canine GLP-1 likely 2028-2029. We're watching the signal so you don't have to.
Get Trial Alerts →